Northern Ireland maps next 20 years' cancer care:
This article was originally published in Clinica
Executive Summary
New cancer screening programmes and services that incorporate the latest technological developments are among the priorities of Northern Ireland's new regional cancer services framework group. The group, will seek to identify key modernisation issues, "in the light of emerging research, new technologies, policy changes and best practice elsewhere". A report to be produced by the end of 2004 will set out a concrete programme of action to 2008, recommendations for service development to 2015 and a "strategic direction" to 2024.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.